Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) and next steps for its Phase 3 pivotal registration program for bremelanotide, its product in development as a novel treatment for female sexual dysfunction (FSD). Palatin will hold a conference call and live audio webcast later today.

End-of-Phase 2 Meeting with FDA on Bremelanotide for FSD
In the end-of-Phase 2 meeting with FDA, Palatin reached preliminary agreement on key aspects of the Phase 3 pivotal registration studies, including:

  • FSD patient population
  • Primary and key secondary efficacy endpoints
  • Study design
  • Dose selection
  • Safety monitoring
  • In addition, the FDA agreed with Palatin's position that the blood pressure and heart rate signals of bremelanotide had been adequately characterized during the Phase 2 program. The FDA also agreed with the proposed Phase 3 blood pressure monitoring program, which will consist of standardized methods for in-clinic assessment of blood pressure.

    "We view our positive meeting with the FDA as a major milestone in the development of bremelanotide for FSD. We are pleased to have concurrence from the FDA on the design and selection of efficacy endpoints of our Phase 3 clinical studies," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are also pleased with the FDA's concurrence that the blood pressure monitoring program for our Phase 3 clinical studies only includes standardized methods for in-clinic assessment of blood pressure. We look forward to advancing bremelanotide for FSD towards a suc
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    3. Palatin Technologies To Present At The 25th Annual ROTH Conference
    4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
    (Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ... barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 ... US$15,000 and a period of expert mentorship from a senior industry figure drawn from ...
    (Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
    (Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... (AFM) is hosting a webinar to provide advanced scientific research into new classes ... bio science and energy. Touted as 'the wonder material of the 21st ...
    Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
    ... recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace ... up in the Merck Vioxx dilemma months ago and its stock ... $25 per share in February. It has recently moved up to ... about 30 percent in the last 12 months. , ,Though Pfizer ...
    ... Controls Inc., which makes auto parts and facility-control systems, reported ... on sales of $7.1 billion. , ,That's up from $158 ... quarter a year ago. , ,"We have faced unprecedented challenges ... result, have accelerated actions to help ensure our company's competitiveness," ...
    ... Accountability Act privacy deadline two years ago, the security ... compliance and many companies may not yet be compliant. ... HIPAA rule involves too many software protocols throughout the healthcare ... admitting that it can't comply with a guideline moves a ...
    Cached Biology Technology:Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6As HIPAA deadline passes even the unprepared are safe for now 2As HIPAA deadline passes even the unprepared are safe for now 3
    (Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
    (Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
    (Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
    Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
    ... papers appearing in the prestigioous journal Science ... Besansky, a professor of biological sciences and a member ... University of Notre Dame, provided evidence that Anopheles gambiae, ... the malaria parasite in Sub-Saharan Africa, is evolving into ...
    ... a mouse that can run on a treadmill twice ... supply of acetylcholine, the neurotransmitter essential for muscle contraction., ... could lead to new treatments for neuromuscular disorders such ... fail to reach the muscles, said Randy Blakely, Ph.D., ...
    ... While Yellowstone,s celebrated bison may be among the ... habits and increasing numbers have raised questions about the ... the National Park Service has partnered with Syracuse University ... climate change and herbivores on the park,s grasslands over ...
    Cached Biology News:New study examines immunity in emerging species of a major mosquito carrer of malaria 2Boosting supply of key brain chemical reduces fatigue in mice 2SU biologist partners with National Park Service to study bison grazing in Yellowstone 2SU biologist partners with National Park Service to study bison grazing in Yellowstone 3
    Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    ... PP2A1, purified Formulation: 50mM ... 0.02% Brij-35, 0.2mM PMSF, 1mM ... glycerol. Properites: PP2A1 (Protein Phosphatase ... DEAE-Sephadex, ammonium sulfate precipitation, QSepharose,amino-hexyl ...
    Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
    Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
    Biology Products: